Literature DB >> 17325863

Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.

Maria Teresa Petrucci, Vincenza Martini, Anna Levi, Cristiano Gallucci, Giovanna Palumbo, Patrizia Del Bianco, Concetta Torromeo, Robin Foà.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325863     DOI： 10.1080/10428190601007570

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Plasma cell leukemia.

Authors:  Moria A Gertz; Francis K Buadi
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Mutsumi Wakabayashi; Keiji Sugimoto; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

4.  Primary plasma cell leukemia and autologous stem cell transplantation.

Authors:  Mary B Drake; Simona Iacobelli; Anja van Biezen; Curly Morris; Jane F Apperley; Dietger Niederwieser; Bo Björkstrand; Gösta Gahrton
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

Review 5.  Plasma cell leukaemia and other aggressive plasma cell malignancies.

Authors:  Taimur Sher; Kena C Miller; George Deeb; Kelvin Lee; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2010-08       Impact factor: 6.998

Review 6.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 7.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

Review 8.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

9.  Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.

Authors:  Giampaolo Talamo; Nathan G Dolloff; Kamal Sharma; Junjia Zhu; Jozef Malysz
Journal:  Rare Tumors       Date:  2012-08-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.